GFM
ABCL icon

GF Fund Management’s AbCellera Biologics ABCL Stock Holding History

GF Fund Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Sell
6,414
-282
-4% -$1.38K ﹤0.01% 390
2026
Q1 		$23.4K Buy
6,696
+814
+14% +$2.93K ﹤0.01% 486
2025
Q4 		$20.1K Sell
5,882
-547
-9% -$2.44K ﹤0.01% 509
2025
Q3 		$32.3K Sell
6,429
-1,134
-15% -$5K ﹤0.01% 435
2025
Q2 		$25.9K Hold
7,563
– – ﹤0.01% 472
2025
Q1 		$16.9K Buy
7,563
+1,361
+22% +$3.9K ﹤0.01% 520
2024
Q4 		$18.2K Buy
+6,202
New +$17.3K ﹤0.01% 482

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

GF Fund Management's ABCL Position: Q2 2026 in Review

GF Fund Management reduced its AbCellera Biologics (ABCL) stake by 4.2% in Q2 2026, selling an estimated $1.38K and leaving 6,414 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #390.

GF Fund Management first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • GF Fund Management held 6,414 shares of AbCellera Biologics worth $50.4K as of Q2 2026.
  • GF Fund Management sold 282 AbCellera Biologics shares in Q2 2026, an estimated $1.38K.
  • AbCellera Biologics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #390 holding.
  • GF Fund Management first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.